Inhibrx (INBX) Competitors $12.16 +0.00 (+0.01%) As of 09:51 AM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock INBX vs. NUVB, CRON, EOLS, XERS, LENZ, IMNM, RCKT, XNCR, ABUS, and PHVSShould you be buying Inhibrx stock or one of its competitors? The main competitors of Inhibrx include Nuvation Bio (NUVB), Cronos Group (CRON), Evolus (EOLS), Xeris Biopharma (XERS), LENZ Therapeutics (LENZ), Immunome (IMNM), Rocket Pharmaceuticals (RCKT), Xencor (XNCR), Arbutus Biopharma (ABUS), and Pharvaris (PHVS). These companies are all part of the "pharmaceutical products" industry. Inhibrx vs. Nuvation Bio Cronos Group Evolus Xeris Biopharma LENZ Therapeutics Immunome Rocket Pharmaceuticals Xencor Arbutus Biopharma Pharvaris Nuvation Bio (NYSE:NUVB) and Inhibrx (NASDAQ:INBX) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, valuation, risk, earnings, media sentiment, dividends, profitability, community ranking and analyst recommendations. Does the MarketBeat Community favor NUVB or INBX? Nuvation Bio received 24 more outperform votes than Inhibrx when rated by MarketBeat users. Likewise, 80.88% of users gave Nuvation Bio an outperform vote while only 58.49% of users gave Inhibrx an outperform vote. CompanyUnderperformOutperformNuvation BioOutperform Votes5580.88% Underperform Votes1319.12%InhibrxOutperform Votes3158.49% Underperform Votes2241.51% Do institutionals and insiders believe in NUVB or INBX? 61.7% of Nuvation Bio shares are held by institutional investors. Comparatively, 82.5% of Inhibrx shares are held by institutional investors. 5.1% of Nuvation Bio shares are held by insiders. Comparatively, 22.2% of Inhibrx shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth. Which has stronger valuation and earnings, NUVB or INBX? Nuvation Bio has higher revenue and earnings than Inhibrx. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioNuvation Bio$7.87M89.69-$75.80M-$2.26-0.92Inhibrx$200K880.21-$154.96MN/AN/A Do analysts rate NUVB or INBX? Nuvation Bio currently has a consensus price target of $7.83, suggesting a potential upside of 275.70%. Given Nuvation Bio's stronger consensus rating and higher probable upside, equities research analysts plainly believe Nuvation Bio is more favorable than Inhibrx.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Nuvation Bio 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 1 Strong Buy rating(s) 3.20Inhibrx 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 Does the media refer more to NUVB or INBX? In the previous week, Nuvation Bio had 5 more articles in the media than Inhibrx. MarketBeat recorded 7 mentions for Nuvation Bio and 2 mentions for Inhibrx. Inhibrx's average media sentiment score of 1.74 beat Nuvation Bio's score of 0.95 indicating that Inhibrx is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Nuvation Bio 2 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Inhibrx 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Is NUVB or INBX more profitable? Nuvation Bio's return on equity of -21.89% beat Inhibrx's return on equity.Company Net Margins Return on Equity Return on Assets Nuvation BioN/A -21.89% -17.86% Inhibrx N/A -113.74%-80.56% SummaryNuvation Bio beats Inhibrx on 11 of the 15 factors compared between the two stocks. Get Inhibrx News Delivered to You Automatically Sign up to receive the latest news and ratings for INBX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart INBX vs. The Competition Export to ExcelMetricInhibrxBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$178.85M$2.89B$5.35B$7.51BDividend YieldN/A1.91%5.44%4.33%P/E RatioN/A30.5321.9818.05Price / Sales880.21476.12396.58104.31Price / CashN/A168.6838.2034.62Price / BookN/A3.716.734.14Net Income-$154.96M-$72.06M$3.21B$247.59M7 Day Performance6.02%8.74%3.97%3.51%1 Month Performance-17.38%-9.15%-7.02%-5.80%1 Year Performance-64.63%-21.05%15.37%2.83% Inhibrx Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)INBXInhibrx2.1446 of 5 stars$12.16+0.0%N/A-64.4%$178.85M$200,000.000.00166News CoveragePositive NewsNUVBNuvation Bio3.1822 of 5 stars$2.03+1.8%$8.75+332.1%-22.5%$673.97M$7.87M-0.9360Analyst ForecastPositive NewsCRONCronos Group1.6637 of 5 stars$1.72-1.7%$3.50+103.5%-27.5%$662.90M$117.62M-13.23450EOLSEvolus3.5864 of 5 stars$10.27+7.7%$24.67+140.2%-4.0%$653.04M$266.27M-11.29170Gap UpHigh Trading VolumeXERSXeris Biopharma4.1788 of 5 stars$4.16flat$6.10+46.6%+132.0%$640.39M$203.07M-9.24290Positive NewsGap UpLENZLENZ Therapeutics1.8485 of 5 stars$23.24+14.7%$44.17+90.0%+69.3%$640.10MN/A-4.87110Gap UpIMNMImmunome2.5612 of 5 stars$7.35+3.5%$25.14+242.1%-42.0%$639.09M$9.04M-0.9140Positive NewsGap UpRCKTRocket Pharmaceuticals4.6515 of 5 stars$5.91+12.1%$43.00+627.6%-69.8%$630.18MN/A-2.15240News CoveragePositive NewsGap UpHigh Trading VolumeXNCRXencor3.34 of 5 stars$8.94+4.7%$34.38+284.5%-40.7%$629.93M$110.49M-2.79280Analyst ForecastAnalyst RevisionNews CoverageABUSArbutus Biopharma2.0948 of 5 stars$3.28+4.5%$5.50+67.7%+17.8%$628.05M$6.17M-7.6390Upcoming EarningsNews CoverageGap UpPHVSPharvaris1.4376 of 5 stars$12.62+5.2%$40.50+220.9%-30.4%$627.48MN/A-4.5130 Related Companies and Tools Related Companies Nuvation Bio Alternatives Cronos Group Alternatives Evolus Alternatives Xeris Biopharma Alternatives LENZ Therapeutics Alternatives Immunome Alternatives Rocket Pharmaceuticals Alternatives Xencor Alternatives Arbutus Biopharma Alternatives Pharvaris Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:INBX) was last updated on 4/24/2025 by MarketBeat.com Staff From Our PartnersFeds Just Admitted It—They Can Take Your CashHere’s the cold truth: If your money is sitting idle in a bank account, it’s vulnerable. That’s why thousan...Priority Gold | SponsoredTrump Orders 'National Digital Asset Stockpile'‘Digital Asset Reserve’ for THIS Coin??? Get all the details before this story gains even more tractionCrypto 101 Media | SponsoredM.A.G.A. is Finished – This Could be even BetterYou’ve no doubt heard Trump’s rally cry: Make America Great Again. But recently the President made a big ch...Paradigm Press | SponsoredMost gold “analysts” aren’t really gold analysts… [watch out]People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “g...Golden Portfolio | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowMy friends Joel and Adam have a simple motto: "For us, it's always a bull market." That’s because their 92%...Crypto Swap Profits | SponsoredThe Exact July Date the AI Correction Will End?AI stocks have cooled off—but Jeff Brown, the tech expert who picked Nvidia before it soared 222x, says one da...Brownstone Research | SponsoredThis Is The Moment You Betray Trump (Or Prove Them Wrong)They said you wouldn’t last—that Bidenflation, Wall Street selloffs, and DEI funds would break your loyalty to...Colonial Metals | SponsoredVirtually Limitless Energy?A radical energy breakthrough could change everything. Scientists at MIT and a stealth startup may have discov...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Inhibrx, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Inhibrx With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy INBX Stock Free INBX Stock Alerts